U-M researchers conducted first human trials of ketamine

Author | Lauren Talley

Close-up of a nurse's hands holding a syringe of ketamine that she is attaching to IV tubing
Photo by Leisa Thompson

Before it was studied as a treatment for depression and chronic pain, scientists developed ketamine as a safer alternative to an earlier anesthetic, PCP.

In the 1960s, chemists at Detroit-based pharmaceutical company Parke-Davis reached out to U-M to study ketamine.

In 1965, U-M pharmacology professor emeritus Edward F. Domino and anesthesiology professor Guenter Corssen published results of the first human trial of ketamine. The 20 subjects had good blood pressure, respiration rate, and other vital signs. And the risk of death was significantly lower compared to other general anesthetics available at the time.

Domino and Corssen also collaborated on the first clinical trial of ketamine. They published results in 1966 showing ketamine was a safe anesthetic in the 130 subjects undergoing surgery. Because of its short-acting pain-relieving properties, ketamine became a widely-used battlefield anesthetic in the Vietnam War.

The subjects of the 1965 study were people incarcerated at Jackson State Prison. The study was overseen by an ethics committee, and in 2017 Domino said, “To this day, NIH guidelines for prison research are based on what happened here.”

Sources:
Garber, Ken. “Listening to Ketamine: An anesthetic with Michigan roots is pulling people from the depths of depression.” Ann Arbor Observer, November 2022

Denomme, Nicholas. “The Domino Effect: Ed Domino’s early studies of Psychoactive Drugs.” Journal of Psychoactive Drugs, 50:4, 298-305,DOI: 10.1080/02791072.2018.1506599

Featured News & Stories

 Child getting ivermectin treatment for river blindness
Health Lab

Commentary: Global health research makes America richer and healthier

Commentary about how global health research can produce treatments, knowledge and economic benefits that advantage wealthy countries in unexpected ways.
 A stylized digital image of an X-ray of a human skeleton superimposed on a strand of DNA
Health Lab

Bigger data reveals the second, third, and fourth switches controlling a gene

A University of Michigan study reveals the untapped potential of the NIH-sponsored Trans-Omics for Precision Medicine (TOPMed) program
 Medicaid magnifying glass
Health Lab

What’s changing in Medicaid and what can you do?

With eligibility rules for people with lower incomes changing in every state, it’s important to stay up to date, seek trustworthy sources and not fall for misinformation
 layers of skin pink to yellow
Health Lab

Study outlines a new framework for direct cell reprogramming

In a new paper published in the journal iScience, Lindsey Muir, Ph.D. and her lab at Michigan Medicine propose a framework for direct cell reprogramming.
 people crowd aerial network connections
Health Lab

New insight into how lipodystrophy can affect overall health

What is lipodystrophy? Expert insights on partial vs. generalized fat loss, health complications, leptin therapy, and emerging clinical research.
 Minding memory above a microphone on a blue background
Minding Memory

Is the United States Lagging Behind Europe in Memory Improvement?

In this episode, Lauren & Matt speak with Neil Mehta, PhD who is the associate dean for research and a professor in the Department of Epidemiology at the University of Texas Medical Branch in Galveston. Dr. Mehta’s research focuses on US life expectancy trends, the effects of obesity on disability and mortality, the sources of socioeconomic status disparities in mortality, and patterns of health in the United States and Europe. Dr. Mehta talks about a recent manuscript from the NIA-funded TRENDS study called “Trends in Memory Function and Memory Impairment Among Older Adults in the United States and Europe, 1996 to 2018.”, which looks at data from several sources to compare trends in memory function across 13 different countries.